Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pramipexole
Drug ID BADD_D01817
Description Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867]. It was first approved by the FDA in 1997 [L5882]. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over time [A176858]. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861]. This increase may be attributed to an aging population along with other contributing factors [A176861]. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873]. RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].
Indications and Usage This drug is indicated for the symptomatic treatment of Parkinson’s disease [FDA label]. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) [FDA label].
Marketing Status approved; investigational
ATC Code N04BC05
DrugBank ID DB00413
KEGG ID D05575
MeSH ID D000077487
PubChem ID 119570
TTD Drug ID D0G8NN
NDC Product Code 31722-910; 31722-906; 10370-305; 31722-909; 31722-911; 31722-907; 31722-908; 10370-253
UNII 83619PEU5T
Synonyms Pramipexole | 4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazole-diamine | Pramipexol | 2-Amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole | Dexpramipexole | Pramipexol, (R)-isomer | Mirapex | Pramipexol Dihydrobromide, (+-)-isomer | Pramipexol Dihydrochloride, (S)-isomer | Pramipexole Dihydrochloride Anhydrous | Sifrol | SND 919CL2x | SND919CL2x | SND-919CL2x | SND-919 | SND 919 | KNS 760704 | KNS760704 | KNS-760704 | Pramipexol, (+-)-isomer | Pramipexole Dihydrochloride | Pramipexole Hydrochloride Monohydrate | 2-Amino-6-propylaminotetrahydrobenzothiazole | 2 Amino 6 propylaminotetrahydrobenzothiazole | 6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
Chemical Information
Molecular Formula C10H17N3S
CAS Registry Number 104632-26-0
SMILES CCCNC1CCC2=C(C1)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.000750%Not Available
Lymphadenitis01.09.01.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoedema24.09.01.001; 01.09.01.006--
Lymphoma01.12.01.001; 16.20.01.001--Not Available
Macular degeneration06.09.03.001--Not Available
Malaise08.01.01.003--
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Mania19.16.02.0020.001021%
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Memory impairment19.20.01.003; 17.03.02.0030.001451%
Menopausal symptoms21.02.02.002--Not Available
Metabolic alkalosis14.01.02.004--Not Available
Metastases to lung22.08.01.005; 16.22.02.002--Not Available
Micturition urgency20.02.02.006--
Middle insomnia19.02.01.003; 17.15.03.003--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.0010.000622%Not Available
Motion sickness17.02.12.001; 04.04.01.001--Not Available
Movement disorder17.01.02.0100.000510%Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.001659%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.0050.000702%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.0070.000159%
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myoclonus17.02.05.0080.000319%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene